These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 8705756)

  • 1. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
    Bowker TJ; Clayton TC; Ingham J; McLennan NR; Hobson HL; Pyke SD; Schofield B; Wood DA
    Heart; 1996 Apr; 75(4):334-42. PubMed ID: 8705756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.
    Eur Heart J; 1997 Oct; 18(10):1569-82. PubMed ID: 9347267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.
    EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events
    Lancet; 2001 Mar; 357(9261):995-1001. PubMed ID: 11293642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.
    EUROASPIRE II Study Group
    Eur Heart J; 2001 Apr; 22(7):554-72. PubMed ID: 11259143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.
    Kotseva K; Wood D; De Bacquer D; De Backer G; Rydén L; Jennings C; Gyberg V; Amouyel P; Bruthans J; Castro Conde A; Cífková R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pajak A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D;
    Eur J Prev Cardiol; 2016 Apr; 23(6):636-48. PubMed ID: 25687109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK.
    Kotseva K; Jennings CS; Turner EL; Mead A; Connolly S; Jones J; Bowker TJ; Wood DA;
    Heart; 2012 Jun; 98(11):865-71. PubMed ID: 22581735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland.
    Sigurdsson EL; Jónsson JS; Thorgeirsson G
    Scand J Prim Health Care; 2002 Mar; 20(1):10-5. PubMed ID: 12086276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of secondary prevention of coronary heart disease. Results of the EUROSPIRE study in the Munster region].
    Enbergs A; Liese A; Heimbach M; Kerber S; Scheld HH; Breithardt G; Kleine-Katthöfer P; Keil U
    Z Kardiol; 1997 Apr; 86(4):284-91. PubMed ID: 9235800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013.
    Kotseva K; De Bacquer D; Jennings C; Gyberg V; De Backer G; Rydén L; Amouyel P; Bruthans J; Cifkova R; Deckers JW; De Sutter J; Fraz Z; Graham I; Keber I; Lehto S; Moore D; Pajak A; Wood D;
    Glob Heart; 2017 Dec; 12(4):315-322.e3. PubMed ID: 26994643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [EUROASPIRE: survey conducted by the European Society of Cardiology on secondary prevention of coronary disease. Hungarian results].
    Ostör E; Jánosi A; Belatiny KA; Borbás S; Bradak A; Podmaniczky M
    Orv Hetil; 1999 Jan; 140(5):243-8. PubMed ID: 10064978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations for secondary prevention of the clinical coronary cardiopathy].
    Rev Esp Cardiol; 1985; 38(1):14-20. PubMed ID: 2858911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifestyle and physiological risk factor profiles six weeks after an acute cardiac event: are patients achieving recommended targets for secondary prevention?
    Murphy BM; Worcester MU; Goble AJ; Mitchell F; Navaratnam H; Higgins RO; Elliott PC; Le Grande MR
    Heart Lung Circ; 2011 Jul; 20(7):446-51. PubMed ID: 21440501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Secondary prevention of coronary disease--at the turn of the millennium in light of the Hungarian data of the EUROASPIRE I-II. Studies].
    Ostör E; Jánosi A; Adám Z; Bárczy G; Borbás S; Dávid B; Gallai I; Podmaniczky M; Ruzsányi T
    Orv Hetil; 2003 Dec; 144(49):2399-404. PubMed ID: 14725205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure is insufficiently controlled in European patients with established coronary heart disease.
    Boersma E; Keil U; De Bacquer D; De Backer G; Pyörälä K; Poldermans D; Leprotti C; Pilotto L; de Swart E; Deckers JW; Heidrich J; Sans S; Kotseva K; Wood D; Ambrosio GB;
    J Hypertens; 2003 Oct; 21(10):1831-40. PubMed ID: 14508188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):121-37. PubMed ID: 19287307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential for cholesterol lowering in secondary prevention of coronary heart disease in europe: findings from EUROASPIRE study. European Action on Secondary Prevention through Intervention to Reduce Events.
    Vanuzzo D; Pilotto L; Ambrosio GB; Pyörälä K; Lehto S; De Bacquer D; De Backer G; Wood D;
    Atherosclerosis; 2000 Dec; 153(2):505-17. PubMed ID: 11164441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for pharmaceutical care in the prevention of coronary heart disease: an exploratory study in acute myocardial infarction patients.
    Chinwong S; Reid F; McGlynn S; Hudson S; Flapan A
    Pharm World Sci; 2004 Apr; 26(2):96-101. PubMed ID: 15085944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cracovian Program for Secondary Prevention of Ischaemic Heart Disease. The quality of care in the field of secondary prevention of ischaemic heart disease depends on where patients are treated in the postdischarge period].
    Jankowski P; Kawecka-Jaszcz K; Pajak A
    Przegl Lek; 2001; 58 Suppl 6():21-5. PubMed ID: 11873737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and III surveys.
    Pajak A; Jankowski P; Kawecka-Jaszcz K; Surowiec S; Wolfshaut R; Loster M; Batko K; Badacz L; Dubiel JS; Grodecki J; Grodzicki T; Maciejewicz J; Mirek-Bryniarska E; Piotrowski W; Smielak-Korombel W; Tracz W
    Kardiol Pol; 2009 Dec; 67(12):1353-9. PubMed ID: 20054766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.